A5066012772- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Rheumatoid Arthritis Research and Therapies
- Inflammasome and immune disorders
- Ocular Diseases and Behçet’s Syndrome
- Skin Diseases and Diabetes
- Dermatological and COVID-19 studies
- Otitis Media and Relapsing Polychondritis
- Atherosclerosis and Cardiovascular Diseases
- Inflammatory Myopathies and Dermatomyositis
- Lipid metabolism and disorders
- Gout, Hyperuricemia, Uric Acid
NIMTS Hospital
2024
Laiko General Hospital of Athens
2022-2024
National and Kapodistrian University of Athens
2021-2024
Cardiovascular disease (CVD) is the foremost cause of morbidity and deaths in antiphospholipid syndrome (APS), driven by thrombo-inflammation atherothrombosis mechanisms. Metabolic (MetS) a proinflammatory prothrombotic state characterized increased CVD risk. We aimed to evaluate prevalence MetS APS patients compared rheumatoid arthritis (RA) diabetes mellitus (DM) its associations with clinical laboratory patient characteristics vascular ultrasound (US) markers subclinical...
Antiphospholipid syndrome (APS) is characterised by increased cardiovascular morbidity and mortality, related to thrombo-inflammatory atherogenic mechanisms. We examined the achievement of traditional risk factor (CVRF) therapeutic goals in APS versus other high disorders such as rheumatoid arthritis (RA) diabetes mellitus (DM), trends over time.
Vaccination against Sars-CoV-2 has been proven to significantly reduce COVID-19 morbidity and mortality is therefore recommended for the general population, especially seniors with impaired immunity.However, it currently postulated that vaccines could rarely induce autoimmune diseases in previously healthy individuals.We report a case of new-onset anti-melanoma differentiation-associated protein 5 (anti-MDA5) antibody-positive dermatomyositis patient presenting rash fever following third...
Journal Article Accepted manuscript Optimal management of ocular complications in axial spondyloarthritis: rethinking subcutaneous infliximab Get access Eleana Bolla, Bolla Department Rheumatology, 417 Army Share Fund Hospital (NIMTS), Athens, Greece Corresponding author: Rheumatology Department, Monis Petraki 10-12, Athens 11521, Greece, Email address: eleanab94@gmail.com https://orcid.org/0000-0002-7424-5364 Search for other works by this author on: Oxford Academic PubMed Google Scholar...